Loading…
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $9M | $-80M | $-81M | $-82M | -29.6% | - | 13.4% |
| 2024 | $0M | $-69M | $-71M | $-52M | -22.0% | - | 11.4% |
| 2023 | $0M | $-56M | $-64M | $-38M | 36.8% | - | 60.8% |
| 2022 | $0M | $-39M | $-40M | $-36M | 35.3% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 8.99 |
| Operating Revenue | 0 | 0 | 0 | 8.99 |
| Operating Expense | 39.97 | 48.40 | 78.19 | 101.78 |
| Research And Development | 30.52 | 33.89 | 59.04 | 73.97 |
| Selling General And Administration | 9.45 | 14.51 | 19.16 | 27.81 |
| Total Expenses | 39.97 | 48.40 | 78.19 | 101.78 |
| Operating Income | -39.97 | -48.40 | -78.19 | -92.78 |
| Total Operating Income As Reported | -39.97 | -48.40 | -78.19 | -92.78 |
| EBITDA | -39.35 | -55.90 | -68.58 | -79.69 |
| Normalized EBITDA | -39.38 | -45.81 | -68.40 | -79.48 |
| EBIT | -39.48 | -56.06 | -68.74 | -79.91 |
| Interest Income | 0.46 | 2.43 | 9.63 | 13.09 |
| Interest Expense | 0.24 | 7.79 | 2.37 | 0.70 |
| Net Interest Income | 0.22 | -5.36 | 7.26 | 12.39 |
| Other Income Expense | 0.02 | -10.09 | -0.18 | -0.21 |
| Interest Income Non Operating | 0.46 | 2.43 | 9.63 | 13.09 |
| Interest Expense Non Operating | 0.24 | 7.79 | 2.37 | 0.70 |
| Net Non Operating Interest Income Expense | 0.22 | -5.36 | 7.26 | 12.39 |
| Pretax Income | -39.72 | -63.85 | -71.11 | -80.60 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | -39.72 | -63.85 | -71.11 | -80.60 |
| Net Income From Continuing And Discontinued Operation | -39.72 | -63.85 | -71.11 | -80.60 |
| Net Income From Continuing Operation Net Minority Interest | -39.72 | -63.85 | -71.11 | -80.60 |
| Net Income | -39.72 | -63.85 | -71.11 | -80.60 |
| Net Income Common Stockholders | -39.72 | -63.85 | -71.11 | -80.60 |
| Net Income Including Noncontrolling Interests | -39.72 | -63.85 | -71.11 | -80.60 |
| Normalized Income | -39.74 | -53.76 | -70.93 | -80.39 |
| Diluted NI Availto Com Stockholders | -39.72 | -63.85 | -71.11 | -80.60 |
| Basic Average Shares | 1.67 | 20.12 | 10.73 | - |
| Diluted Average Shares | 1.67 | 20.12 | 10.73 | - |
| Reconciled Depreciation | 0.13 | 0.16 | 0.17 | 0.21 |
| Total Unusual Items | 0.02 | -10.09 | -0.18 | -0.21 |
| Total Unusual Items Excluding Goodwill | 0.02 | -10.09 | -0.18 | -0.21 |
| Special Income Charges | - | 0 | -0.25 | 0 |
| Other Special Charges | - | - | 0.25 | - |
| Gain On Sale Of Security | 0.02 | -10.09 | 0.07 | -0.21 |
| General And Administrative Expense | 9.45 | 14.51 | 19.16 | 27.81 |
| Other Gand A | 9.45 | 14.51 | 19.16 | 27.81 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| BioAge Labs, Inc.this co. | BIOA | $757M | -9.39 | 2.78 | -29.6% | -7.19 |
| Eton Pharmaceuticals, Inc. | ETON | $792M | -172.06 | 30.27 | -17.6% | 248.97 |
| Phathom Pharmaceuticals, Inc. | PHAT | $786M | -3.55 | -1.79 | 50.5% | -5.69 |
| Kura Oncology, Inc. | KURA | $779M | - | 4.47 | -160.0% | - |
| Geron Corporation | GERN | $776M | -9.30 |
| 3.44 |
| -37.0% |
| -16.53 |
| EVMN | EVMN | $745M | -10.82 | 3.63 | -33.5% | -8.82 |
| Omeros Corporation | OMER | $742M | -221.45 | -6.12 | 2.8% | -7.97 |
| HealthStream, Inc. | HSTM | $739M | 40.28 | 2.09 | 5.2% | 11.26 |
| Bright Minds Biosciences Inc. | DRUG | $731M | -59.77 | 8.91 | -14.9% | -46.77 |
| Peer Median | - | -10.82 | 3.53 | -16.2% | -7.97 | |